Key result
Small molecule immunosuppressants worsen CV risks, driving ischemic and nonischemic cardiac disease.
Answers are grounded in this paper and cite their sources.
Review outlines negative cardiovascular outcomes from small molecule immunosuppressants, highlighting elevated risks of ischemic heart disease and nonischemic cardiac effects.
Immunosuppressants are critical after transplantation and prescribed as immune-modulators for autoimmune disorders and glomerulonephritides. Immunosuppressants include large (e.g., thymoglobulin, alemtuzumab, and rituximab) and small molecules (e.g., corticosteroids, calcineurin inhibitors, antimetabolites, and mammalian target of rapamycin (mTOR) inhibitors). The majority of the small molecules worsen traditional cardiovascular risks. This review describes cardiovascular risks of small molecule immunosuppressants: corticosteroids, calcineurin inhibitors (tacrolimus and cyclosporine), and mTOR inhibitors (rapamycin), by categorizing these risks into two categories: ischemic heart disease and nonischemic cardiac effects.
No takes yet. Share an insight, caveat, or question.
Chakkera et al. (2017) conducted a review in Transplantation, autoimmune disorders, and glomerulonephritides. Small molecule immunosuppressants (corticosteroids, calcineurin inhibitors, mTOR inhibitors) was evaluated on Ischemic heart disease and nonischemic cardiac effects. Small molecule immunosuppressants (corticosteroids, calcineurin inhibitors, and mTOR inhibitors) worsen traditional cardiovascular risks, leading to ischemic and nonischemic cardiac effects.
Synapse has enriched 10 related papers. Consider them for comparative context: